<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="used by anyone for any lawful purpose. Abstract Background While" exact="ribavirin" post="mono-therapy regimens have minimal effect on patients with chronic"/>
 <result pre="with interferon. Clinical studies show that interferon-free combination therapies containing" exact="ribavirin" post="are also efficacious, suggesting that an interferon-free therapy could"/>
 <result pre="the treatment. Therefore, understanding the mechanism of HCV resistance to" exact="ribavirin" post="and cross resistance to other antiviral drugs could be"/>
 <result pre="Methods We tested the ability of a J6/JFH1 derived HCV" exact="ribavirin" post="resistant mutant to grow in tissue cultured Huh7D cells"/>
 <result pre="mutations. Conclusions These results indicate that determinants of resistance to" exact="ribavirin" post="could also confer resistance to other anti-HCV drugs, shedding"/>
 <result pre="drugs, shedding light toward understanding the mechanism of action of" exact="ribavirin" post="and highlighting the importance of combination drug selection for"/>
 <result pre="patients consists of a combination of pegylated interferon alpha and" exact="ribavirin" post="[4]. Recently, two protease inhibitors were approved by the"/>
 <result pre="HCV infections is highly desirable. Recent studies have shown that" exact="ribavirin" post="in combination with other antiviral drugs, without interferon, can"/>
 <result pre="be efficacious [7], [8], suggesting that an interferon-free therapy containing" exact="ribavirin" post="could be adopted in the near future. However, generation"/>
 <result pre="treatment. In addition, the anti HCV mechanism of action of" exact="ribavirin" post="is not completely elucidated. Several mechanisms of action of"/>
 <result pre="ribavirin is not completely elucidated. Several mechanisms of action of" exact="ribavirin" post="against HCV were proposed including a direct effect against"/>
 <result pre="[10]. In order to study the cross-resistance of HCV to" exact="ribavirin" post="and other antiviral drugs that could have a mechanism"/>
 <result pre="we tested the ability of a J6/JFH1 [11] HCV derived" exact="ribavirin" post="resistant mutant, HCV-RR [12], to grow in the presence"/>
 <result pre="a similar lethal mutagenic effect has also been observed for" exact="ribavirin" post="on several viruses including poliovirus [17], coxsackievirus B3 [18],"/>
 <result pre="[21], and Hantaan virus [22]. It has been shown that" exact="ribavirin" post="also has a mutagenic effect on HCV, increasing its"/>
 <result pre="in vivo [25], [27]. Deep sequencing has recently revealed that" exact="ribavirin" post="exerts mutagenic activity in chronic HCV infected patients by"/>
 <result pre="cell-free biochemical assays [36]. It has also been shown that" exact="ribavirin" post="antagonizes the in vitro anti-HCV activity of 2′-C-Methylcytidine [37],"/>
 <result pre="this study we show that an HCV mutant resistant to" exact="ribavirin" post="is more resistant than parental J6/JFH1 to 5-Fluorouracil, but"/>
 <result pre="resistant than parental J6/JFH1 to 2′-C-Methylcytidine. These results indicate that" exact="ribavirin" post="resistant viruses could have elevated resistance to other inhibitors,"/>
 <result pre="light toward the understanding of the mechanism of action of" exact="ribavirin" post="and HCV resistance to this drug. In addition, the"/>
 <result pre="5-Fluorouracil In order to test the sensitivity of an HCV" exact="ribavirin" post="resistant mutant to 5-Fluorouracil, parental J6/JFH1 [11] and J6/JFH1"/>
 <result pre="of 2′-C-Methylcytidine In order to test sensitivity of an HCV" exact="ribavirin" post="resistant mutant to 2′-C-Methylcytidine, parental J6/JFH1 and HCV-RR2 were"/>
 <result pre="of the drug (Figure 4) and are still resistant to" exact="ribavirin" post="(not shown). Figure 4 Further passage of HCV in"/>
 <result pre="In this study we compared the growth of an HCV" exact="ribavirin" post="resistant mutant (HCV-RR2) to the growth of its parental"/>
 <result pre="the nucleoside analog 2′-C-Methylcytidine. We show that HCV resistant to" exact="ribavirin" post="is more resistant to 5-Fluorouracil but is not more"/>
 <result pre="along the genome (Table 1). The mechanism of action of" exact="ribavirin" post="against HCV in vitro and in vivo and the"/>
 <result pre="vitro and in vivo and the mechanism of resistance to" exact="ribavirin" post="by HCV ribavirin resistant mutants has not been completely"/>
 <result pre="vivo and the mechanism of resistance to ribavirin by HCV" exact="ribavirin" post="resistant mutants has not been completely elucidated. The differential"/>
 <result pre="fact that 5-Fluorouracil is a pyrimidine analog and 2′-C-Methylcytidine and" exact="ribavirin" post="are both nucleoside analogs. Given the nature of these"/>
 <result pre="nature of these drugs, it is tempting to speculate that" exact="ribavirin" post="acts on HCV at the RNA replication level, as"/>
 <result pre="shown for 2′-C-Methylcytidine [36]. We previously showed that an HCV" exact="ribavirin" post="resistant mutant has mutations in different positions of its"/>
 <result pre="that the RNA dependent RNA polymerase from HCV can use" exact="ribavirin" post="triphosphate as a nucleotide substrate. Once ribavirin monophosphate has"/>
 <result pre="HCV can use ribavirin triphosphate as a nucleotide substrate. Once" exact="ribavirin" post="monophosphate has been incorporated in the nascent chain, it"/>
 <result pre="RNA elongation [38], [39]. As noted above, mutagenic activity of" exact="ribavirin" post="on HCV has been observed in vivo and in"/>
 <result pre="its parental J6/JFH1. This indicates that determinants conferring resistance to" exact="ribavirin" post="also confer resistance to 5-Fluorouracil and could confer resistance"/>
 <result pre="drug treatments. Given the observed efficacy of the inclusion of" exact="ribavirin" post="in interferon free regimens in the treatment of chronic"/>
 <result pre="the treatment of chronic HCV, cross resistance of HCV to" exact="ribavirin" post="and to other antiviral drugs could be of major"/>
 <result pre="In FMDV, a single point mutation (M296I) confers resistance to" exact="ribavirin" post="[40]. This mutant was as sensitive as wild type"/>
 <result pre="the action of antiviral drugs. Of note, the concentrations of" exact="ribavirin" post="(5 mM) and 5-Fluorouracil (200 or 500 µg/ml) for"/>
 <result pre="[12]. Mutations in the finger domain have been identified in" exact="ribavirin" post="resistant mutants of poliovirus [44], [45]. Five other non-synonymous"/>
 <result pre="viral replication. Conclusion In this report, we show that a" exact="ribavirin" post="resistant mutant of HCV has differential sensitivity to other"/>
 <result pre="suggests that mutations that are responsible for HCV resistance to" exact="ribavirin" post="can be involved in the sensitivity to other drugs,"/>
 <result pre="clinically important for drug selection, since an interferon-free regimen containing" exact="ribavirin" post="for the treatment of HCV infections seems currently plausible."/>
 <result pre="10% bovine calf serum (Atlanta Biologicals), L-glutamine (Gibco), penicillin, and" exact="streptomycin" post="(Gibco). Viruses Virus J6/JFH1 was obtained from plasmid pFL-"/>
 <result pre="ShiffmanML, ReddyKR, SmithC, MarinosG, et al. (2002) Peginterferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection. N Engl J"/>
 <result pre="975–982doi:;10.1056/NEJMoa020047;347/13/97512324553 5ShermanKE, FlammSL, AfdhalNH, NelsonDR, SulkowskiMS, et al. (2011) Response-guided" exact="telaprevir" post="combination treatment for hepatitis C virus infection. N Engl"/>
 <result pre="polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus" exact="ribavirin" post="in hepatitis C. Hepatology. 55: 749–758doi:10.1002/hep.24744 8ZeuzemS, AsselahT, AngusP,"/>
 <result pre="the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and" exact="ribavirin" post="in patients with chronic HCV infection. Gastroenterology 1412047–2055: S0016–5085(11)01248-0doi:10.1053/j.gastro.2011.08.051"/>
 <result pre="LiangTJ, et al. (2008) Mechanisms of action of interferon and" exact="ribavirin" post="in chronic hepatitis C: Summary of a workshop. Hepatology47:"/>
 <result pre="ArnoldJJ, ZhongW, LauJY, et al. (2000) The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagen. Nat Med6: 1375–1379.11100123 18GraciJD,"/>
 <result pre="Curing of foot-and-mouth disease virus from persistently infected cells by" exact="ribavirin" post="involves enhanced mutagenesis. Virology 311339–349: S0042682203001442. 20Day CW, Smee"/>
 <result pre="23BrochotE, DuverlieG, CastelainS, MorelV, WychowskiC, et al. (2007) Effect of" exact="ribavirin" post="on the hepatitis C virus (JFH-1) and its correlation"/>
 <result pre="(2002) Viral RNA mutations are region specific and increased by" exact="ribavirin" post="in a full-length hepatitis C virus replication system. J"/>
 <result pre="PoltaA, HerrmannE, MihmU, KronenbergerB, et al. (2007) Mutagenic effect of" exact="ribavirin" post="on hepatitis C nonstructural 5B quasispecies in vitro and"/>
 <result pre="Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells:" exact="ribavirin" post="induces mutagenesis in HCV RNA. J Viral Hepat11: 479–487.15500548"/>
 <result pre="the hepatitis C virus NS5B in patients undergoing treatment with" exact="ribavirin" post="monotherapy. Gastroenterology132: 1757–1766.17484873 28DietzJ, SchelhornSE, FittingD, MihmU, SusserS, et"/>
 <result pre="SusserS, et al. (2013) Deep sequencing reveals mutagenic effects of" exact="ribavirin" post="during monotherapy of hepatitis C virus genotype 1-infected patients."/>
 <result pre="46094–46098.11602568 39VoNV, YoungKC, LaiMM (2003) Mutagenic and inhibitory effects of" exact="ribavirin" post="on hepatitis C virus RNA polymerase. Biochemistry42: 10462–10471.12950173 40SierraM,"/>
</results>
